Pharmaceutical

Dermavant maps out atopic dermatitis filing after positive Phase III data 

Dermavant will include these findings in an upcoming supplemental new drug application (sNDA) submission, which is expected in Q1 2024.

Jan 13, 2024 - 18:00
Dermavant maps out atopic dermatitis filing after positive Phase III data 
Dermavant will include these findings in an upcoming supplemental new drug application (sNDA) submission, which is expected in Q1 2024.
Read the original article

Tags:

Previous Article

Santhera’s Agamree becomes first approved treatment in UK for all DMD patients

Next Article

Ji Xing acquires Biogen’s BIIB131 for acute ischemic stroke

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Hasten Biopharmaceutic raises $315m for pipeline assets development

Hasten Biopharmaceutic raises $315m for pipeline assets...

Apr 20, 2023

STAT+: Amazon strikes partnership with 3M to advance conversational AI in medicine

STAT+: Amazon strikes partnership with 3M to advance co...

Apr 19, 2023

STAT+: Novartis is scolded by U.K. trade group for the third time this year over Entresto marketing

STAT+: Novartis is scolded by U.K. trade group for the ...

Jul 18, 2023